Mineralys outlines pivotal trial timelines for lorundrostat in hypertension
CEO Jon Congleton highlighted the company's focus on advancing its pivotal trials for lorundrostat, targeting dysregulated aldosterone in patients with uncontrolled and resistant hypertension. He ...
CVS Health Stock Jumps on Earnings Beat and Solid Guidance. ‘Phew!’ Says One Analyst.
CVS Health investors were breathing a big sigh of relief Wednesday after the healthcare services behemoth reported ...
Nvidia Stock Gains. Why Stargate and Meta Are in Focus for Investors.
The chip maker is a technology partner for the $500 billion project that aims to accelerate U.S. AI infrastructure.
cryptopolitan8h
10-year Treasury yield continues to creep higher, now at 4.54%
Treasury yields rose following President Trump’s announcement of 25% tariffs on all foreign steel and aluminum entering the ...
Sensata targets flat 2025 revenue with focus on operational excellence and electrification
Q4 2024 Management View CEO Stephan von Schuckmann emphasized his focus on three key pillars for Sensata’s growth: returning to growth, operational performance improvements, and optimizing capital ...
Teradata outlines 2025 growth plans with 14%-18% cloud ARR target and new AI innovations
Cloud ARR for 2025 is projected to grow by 14% to 18%, with Total ARR expected to range from flat to 2% growth. Non-GAAP diluted earnings per share for 2025 is expected to be between $2.15 and $2.25, ...